Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 9/20 | 0.45 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12872730 | 0.89 | DGAT1 (0.44) | KDRKITFLT3DGAT1P2RY1 | |
| SCHEMBL1180881 | 0.88 | P2RY1 (0.45) | KDRKITFLT3DGAT1P2RY1 | |
| SCHEMBL12872589 | 0.87 | NAMPT (0.42) | KDRKITFLT3DGAT1P2RY1 | |
| SCHEMBL12872751 | 0.87 | DGAT1 (0.50) | KDRKITFLT3DGAT1P2RY1 | |
| SCHEMBL12872735 | 0.87 | DGAT1 (0.50) | KDRKITFLT3DGAT1P2RY1 | |
| SCHEMBL12872600 | 0.86 | DGAT1 (0.46) | KDRKITFLT3DGAT1P2RY1 | |
| SCHEMBL13666000 | 0.86 | DGAT1 (0.46) | KDRKITFLT3DGAT1P2RY1 | |
| SCHEMBL13665289 | 0.86 | NAMPT (0.44) | KDRKITFLT3DGAT1P2RY1 | |
| SCHEMBL12872577 | 0.86 | NAMPT (0.43) | KDRKITFLT3DGAT1P2RY1 | |
| SCHEMBL1180647 | 0.86 | KDR (0.47) | KDRKITFLT3DGAT1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324241-B2 | Triazolo compounds useful as DGAT1 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MEYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| WO-2009126624-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034468-A1 | TRIAZOLO COMPOUNDS USEFUL AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | KDR 3540/4885KIT 4786/4885FLT3 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.